Cargando…

The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma

GV1001 is a telomerase-based cancer vaccine made of a 16-mer telomerase reverse transcriptase (TERT) peptide, and human TERT, the rate-limiting subunit of the telomerase complex, is an attractive target for cancer vaccination. The aim of this study was to evaluate the effect of telomerase peptide va...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Joo Kyung, Kim, Yejin, Kim, Hyemin, Jeon, Jane, Kim, Tae Wan, Park, Ji-Hong, Hwnag, Young-il, Lee, Wang Jae, Kang, Jae Seung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342724/ https://www.ncbi.nlm.nih.gov/pubmed/27655706 http://dx.doi.org/10.18632/oncotarget.12057

Ejemplares similares

The Anti-inflammatory Effect of GV1001 Mediated by the Downregulation of ENO1-induced Pro-inflammatory Cytokine Production
por: Choi, Jiyea, et al.
Publicado: (2015)

GV1001 interacts with androgen receptor to inhibit prostate cell proliferation in benign prostatic hyperplasia by regulating expression of molecules related to epithelial-mesenchymal transition
por: Kim, Yejin, et al.
Publicado: (2021)

Protective effects of GV1001 on myocardial ischemia-reperfusion injury
por: Chang, Ji-Eun, et al.
Publicado: (2017)

GV1001 Inhibits the Severity of the Ligature-Induced Periodontitis and the Vascular Lipid Deposition Associated with the Periodontitis in Mice
por: Kim, Sharon Y., et al.
Publicado: (2023)

Novel Peptide Vaccine GV1001 Rescues Hearing in Kanamycin/Furosemide-Treated Mice
por: Kim, Shin Hye, et al.
Publicado: (2018)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Neuroprotective Effects of GV1001 in Animal Stroke Model and Neural Cells Subject to Oxygen-Glucose Deprivation/Reperfusion Injury
por: Kwon, Hyuk Sung, et al.
Publicado: (2021)

The Telomerase-Derived Anticancer Peptide Vaccine GV1001 as an Extracellular Heat Shock Protein-Mediated Cell-Penetrating Peptide
por: Kim, Hong, et al.
Publicado: (2016)

hTERT peptide fragment GV1001 demonstrates radioprotective and antifibrotic effects through suppression of TGF-β signaling
por: Chen, Wei, et al.
Publicado: (2018)

A novel telomerase-derived peptide GV1001-mediated inhibition of angiogenesis: Regulation of VEGF/VEGFR-2 signaling pathways
por: Kim, Jae Hyeon, et al.
Publicado: (2022)

Outcomes of Peptide Vaccine GV1001 Treatment in a Murine Model of Acute Noise-Induced Hearing Loss
por: Lee, Sang-Yeon, et al.
Publicado: (2020)

Effects of GV1001 on Language Dysfunction in Patients With Moderate-to-Severe Alzheimer’s Disease: Post Hoc Analysis of Severe Impairment Battery Subscales
por: Kwon, Hyuk Sung, et al.
Publicado: (2023)

GV1001 inhibits cell viability and induces apoptosis in castration-resistant prostate cancer cells through the AKT/NF-κB/VEGF pathway
por: Park, Yong Hyun, et al.
Publicado: (2019)

A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer
por: Kim, Sejin, et al.
Publicado: (2022)

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
por: Chae, Heejung, et al.
Publicado: (2020)

Prognostic Value of Sarcopenia and Myosteatosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Kim, Dong Wook, et al.
Publicado: (2022)

Anti-metastatic effect of GV1001 on prostate cancer cells; roles of GnRHR-mediated Gαs-cAMP pathway and AR-YAP1 axis
por: Kim, Ji Won, et al.
Publicado: (2021)

Anti-inflammatory Effect of Alloferon on Ovalbumin-induced Asthma
por: Jeon, Jane, et al.
Publicado: (2015)

Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities
por: Myo Min, Kay K., et al.
Publicado: (2023)

Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial
por: Koh, Seong-Ho, et al.
Publicado: (2021)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Palam, L R, et al.
Publicado: (2015)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
por: Koltai, Tomas, et al.
Publicado: (2022)

Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
por: Nishi, Hidemi, et al.
Publicado: (2023)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Anatomical features of the GV20 acupoint
por: Kim, Sang Hyun, et al.
Publicado: (2023)

TPH1 and 5-HT(7) Receptor Overexpression Leading to Gemcitabine-Resistance Requires Non-Canonical Permissive Action of EZH2 in Pancreatic Ductal Adenocarcinoma
por: Chaudhary, Prakash, et al.
Publicado: (2021)

Lipocalin2 Promotes Invasion, Tumorigenicity and Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
por: Leung, Lisa, et al.
Publicado: (2012)

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016)

Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation
por: Li, Junjie, et al.
Publicado: (2018)

Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma
por: Miller, Aubrey L., et al.
Publicado: (2020)

Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
por: Takagi, Tadataka, et al.
Publicado: (2023)

Assessment of Factors Associated with the Safety Depth of GV15 Yamen: Factors Associated with the Safety Depth of GV15
por: Park, Soo-Jung, et al.
Publicado: (2014)

Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma
por: Kim, Hyemin, et al.
Publicado: (2021)

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
por: Min, Young Joo, et al.
Publicado: (2002)

Editorial: Interferons and GvHD
por: Kim, Boram, et al.
Publicado: (2022)

Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients
por: Kim, Mi-Ju, et al.
Publicado: (2017)

Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma
por: Rohila, Deepak, et al.
Publicado: (2023)

Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine
por: Fuller, Ryan N, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9r4mqadb40psr7jttrqemjmabl